Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study.

Details

Ressource 1Download: serval:BIB_E48265D3CEA6.P001 (94.66 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_E48265D3CEA6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study.
Journal
Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo
Author(s)
Kiefer T., Hirt C., Späth C., Schüler F., Al-Ali H.K., Wolf H.H., Herbst R., Maschmeyer G., Helke K., Kessler C., Niederwieser D., Busemann C., Schroeder H., Vogelgesang S., Kirsch M., Montemurro M., Krüger W.H., Dölken G., for the Ostdeutsche Studiengruppe Hämatologie und Onkologie
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
2012
Volume
23
Number
7
Pages
1809-1812
Language
english
Notes
Publication types: JOURNAL ARTICLE
Publication Status: ppublish
Abstract
Background We previously reported the results of a phase II study for patients with newly diagnosed primary central nervous system lymphoma treated with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiotherapy (WBRT). Now, we update the initial results. Patients and methods From 1999 to 2004, 23 patients received high-dose methotrexate. In case of at least partial remission, high-dose busulfan/thiotepa (HD-BuTT) followed by aPBSCT was carried out. Patients refractory to induction or without complete remission after HD-BuTT received WBRT. Eight patients still alive in 2011 were contacted and Mini-Mental State Examination (MMSE) and the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire (QLQ)-C30 were carried out. Results Of eight patients still alive, median follow-up is 116.9 months. Only one of nine irradiated patients is still alive with a severe neurologic deficit. In seven of eight patients treated with HD-BuTT, health condition and quality of life are excellent. MMSE and QLQ-C30 showed remarkably good results in patients who did not receive WBRT. All of them have a Karnofsky score of 90%-100%. Conclusions Follow-up shows an overall survival of 35%. In six of seven patients where WBRT could be avoided, no long-term neurotoxicity has been observed and all patients have an excellent quality of life.
Pubmed
Web of science
Open Access
Yes
Create date
07/02/2012 13:53
Last modification date
25/09/2019 6:11
Usage data